Skip to main content
OpenTrials
Completed

NCT Number: NCT01438255

Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice

This is a prospective, non-comparative, open, observational study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Lung Diseases Lung Diseases, Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

6 year–18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Handok Pharmaceuticals

Seoul, South Korea

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Children who is prescribed with ciclesonide for asthma

Exclusion criteria

  • Subjects with contraindications to ciclesonide use
  • Subjects with clinically relevant concomitant disease that could compromise the patient's safety should not be included in this study.

Treatment and study plan

Primary outcomes

  1. Asthma control day

    Time frame: 12weeks

Secondary outcomes

  1. Morning peak expiratory flow

    Time frame: 12weeks

  2. asthma exacerbation

    Time frame: 12weeks

  3. The number of Reliever use

    Time frame: 12weeks

  4. Asthma symptom score

    Time frame: 12weeks

  5. Number of Participants with Adverse Events

    Time frame: 12weeks

Sponsors and collaborators

Lead sponsor

Handok Inc.

Industry

Registry information

Important dates

Study start
2010
Primary completion
2012
First posted
Sep 22, 2011
Registry last updated
Aug 23, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.